The addition of the non-steroidal MR antagonist finerenone on standard care in DKD patients decreased albuminuria and UACR (Katayama et al., 2017; Bakris et al., 2020) and led to improvements in renal endpoints in the FIDELIO-DKD trial (Bakris et al., 2020). The gene discussed is NR3C2; the disease is diabetic kidney disease.